Arcus Biosciences, Inc. Share Price

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - Nyse 21:00:02 24/05/2024 BST 5-day change 1st Jan Change
16.12 USD -0.98% Intraday chart for Arcus Biosciences, Inc. -4.62% -15.60%
Sales 2024 * 274M 21.49B Sales 2025 * 180M 14.14B Capitalization 1.47B 115B
Net income 2024 * -316M -24.81B Net income 2025 * -409M -32.11B EV / Sales 2024 * 2.93 x
Net cash position 2024 * 663M 52.05B Net cash position 2025 * 415M 32.6B EV / Sales 2025 * 5.84 x
P/E ratio 2024 *
-4.48 x
P/E ratio 2025 *
-3.56 x
Employees 577
Yield 2024 *
-
Yield 2025 *
-
Free-Float 59.18%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.98%
1 week-4.62%
Current month+5.84%
1 month+4.47%
3 months-17.46%
6 months+14.65%
Current year-15.60%
More quotes
1 week
16.03
Extreme 16.03
17.56
1 month
14.59
Extreme 14.59
18.07
Current year
14.10
Extreme 14.1
20.31
1 year
12.95
Extreme 12.95
25.47
3 years
12.95
Extreme 12.95
49.10
5 years
6.30
Extreme 6.3
49.10
10 years
6.30
Extreme 6.3
49.10
More quotes
Managers TitleAgeSince
Founder 66 31/12/14
Chief Executive Officer 65 31/12/14
Director of Finance/CFO 51 31/07/20
Members of the board TitleAgeSince
Chief Executive Officer 65 31/12/14
Director/Board Member 63 17/09/17
Director/Board Member 69 30/04/15
More insiders
Date Price Change Volume
24/05/24 16.12 -0.98% 560,498
23/05/24 16.28 -2.81% 796,332
22/05/24 16.75 -2.84% 675,151
21/05/24 17.24 +2.74% 531,073
20/05/24 16.78 -0.71% 483,027

Delayed Quote Nyse, May 24, 2024 at 09:00 pm

More quotes
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.12 USD
Average target price
39 USD
Spread / Average Target
+141.94%
Consensus